Aurinia Pharmaceuticals (AUPH)

• Market cap: $2.11B
• 1 day: -0.87%
• 5 days: 2.9%
• 1 month: 29.94%
• 3 months: 31.55%
• 6 months: 95.95%
• Year to date: 82.1%
• 1 year: 83.35%
• 5 years: 14.23%
• 10 years: 536.25%
• Sector: Healthcare
• Industry: Biotechnology

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 300